Skip to content
DataLookout
Menu

FLECAPRONCT05631730

Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 1 month later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jun 2026 to Aug 2028 Show 4 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised
  2. Minor Primary and study completion dates: Feb 2026 to Jun 2026v7
  3. Notable Eligibility criteria revisedv5
  4. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Dec 2025 to Feb 2026
    • Study completion date: Dec 2027 to Feb 2026
    • Start date changed from estimate of Dec 2022 to Jan 4, 2023
    • Site details revised
  5. Notable Eligibility criteria expanded, about 5 words
    • Start date: Nov 2022 to Dec 2022
    • Secondary endpoints: details revised at 1 of 4 entries
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of ventricular tachyarrhythmias
Timeframe: 12 months

Secondary (4)

Burden of premature ventricular complexes
Change in health-related quality of life
Number of severe ventricular tachycardias
Safety composite

Arms and interventions

Flecainide and MetoprololExperimental

Participants will receive flecainide 50 mg twice daily (BID), with a dosage target of 100 mg BID. The maximum daily dose of flecainide will not exceed 300 mg. The first dose of flecainide will be initiated in-hospital with a 12-lead electrocardiogram (ECG) taken after 3 hours. If the ECG is considered normal after flecainide treatment, the participant will continue with 50 mg BID from the next day. Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. The maximum daily dose of metoprolol will not exceed 200 mg. Within the run-in period, the dosage of both Flecainide and Metoprolol will be increased to the maximum tolerable dose. The Study Team can change the immediate-release formulation of Flecainide to controlled release at the same daily dose of flecainide. Whether metoprolol sustained release will be dosed once daily (QD) or BID, will be up to the investigator and patient preference.

Metoprolol AloneActive comparator

Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. Within the run-in period, the dosage will be increased to the maximum tolerable dose. Whether metoprolol sustained release will be dosed QD or BID, will be up to the investigator and patient preference. The maximum daily dose of metoprolol will not exceed 200 mg.

Drugs: Flecainide, Metoprolol

Sites

1 site in 1 country

  • Oslo University Hospital RikshospitaletOslo, Oslo, Norway